SLAINTE BEOGA TEORANTA

Their core work

Sláinte Beoga Teoranta is an Irish SME developing non-antibiotic treatments for livestock health, with a strong focus on bovine mastitis — one of the costliest diseases in dairy farming. Their core product, PanaMast, is an antimicrobial therapy designed to treat mastitis without contributing to antibiotic resistance. They have expanded into non-medicated feed additives that improve milk yield while reducing methane emissions and replacing antibiotic growth promoters in dairy cattle.

What they specialise in

How they've shifted over time

Sláinte Beoga started with a tight focus on a single veterinary product — a non-antibiotic mastitis treatment — taking it through SME Instrument Phase 1 (feasibility) in 2015 and Phase 2 (commercialization) in 2017. By 2019, they broadened into non-medicated feed additives that address milk productivity, antibiotic growth promoter replacement, and methane reduction simultaneously. The trajectory shows a company expanding from a single-product veterinary startup toward a broader animal health and sustainable dairy platform.

Moving from a single veterinary treatment product toward a broader portfolio addressing antibiotic-free dairy farming and livestock environmental impact — positioning themselves at the intersection of animal health and climate-smart agriculture.

How they like to work

Sláinte Beoga primarily leads their own projects — they coordinated 2 of 3 projects, both through the SME Instrument which funds company-driven innovation. Their one participant role (RumenShield Dairy) shows willingness to join consortia when complementary. With only 3 unique partners across 3 countries, they operate in small, focused teams rather than large consortia, typical of a product-focused SME that prefers tight collaborations over sprawling networks.

A small but focused network of 3 partners across 3 countries, reflecting their SME-stage development. Their partnerships appear project-specific rather than built around a large recurring consortium.

What sets them apart

They are one of very few companies specifically developing non-antibiotic antimicrobial treatments for bovine mastitis — a niche but commercially significant problem costing the European dairy industry billions annually. Their progression through SME Instrument Phase 1 to Phase 2 (with €2.5M funding) signals EU validation of their technology's commercial potential. For anyone working on antibiotic resistance in agriculture or sustainable dairy, they bring a rare combination of product-stage IP and EU-funded clinical evidence.

Highlights from their portfolio

• PanaMast
  Secured €2.5M in SME Phase 2 funding to commercialize a non-antibiotic mastitis treatment — one of the largest single-SME awards in their cohort, indicating strong commercial validation.
• RumenShield Dairy
  Marks the company's strategic expansion from treatment into prevention, addressing milk yield, antibiotic replacement, and methane reduction in a single feed additive product.